Katherine High
About Katherine High
Katherine High serves as the President of Therapeutics at AskBio and has a medical degree. She co-founded Spark Therapeutics and played a key role in developing the first gene therapy, receiving the Jerry Mendell Award from the American Society of Gene and Cell Therapy.
Work at Asklepios BioPharmaceutical
Katherine High serves as the President of Therapeutics at Asklepios BioPharmaceutical, a position she has held since January 2021. In this role, she oversees the development and implementation of therapeutic strategies, focusing on innovative gene therapies. Her leadership is pivotal in advancing the company's mission to provide groundbreaking treatments.
Education and Expertise
Katherine High holds a medical degree (MD), which provides her with a strong foundation in medicine and healthcare. Her educational background supports her expertise in gene therapy and therapeutics, enabling her to contribute significantly to advancements in these fields.
Background
Katherine High is a co-founder of Spark Therapeutics, a company known for its focus on gene therapy. Her experience in founding and leading organizations in the biotechnology sector has equipped her with extensive knowledge and skills in therapeutic development and innovation.
Achievements
Katherine High has been recognized for her contributions to the field of gene therapy. She received the Jerry Mendell Award from the American Society of Gene and Cell Therapy, highlighting her impact and leadership in advancing gene therapy research and applications.
Gene Therapy Development Leadership
Katherine High led the development of the first gene therapy, marking a significant milestone in the field. This achievement underscores her role as a pioneer in gene therapy and her commitment to advancing therapeutic options for patients.